SYRS

Syros Pharmaceuticals Inc. (SYRS) | Rumor.io

Syros Pharmaceuticals

SYRS

Attention (50-day avg)0%

Attention rank (50-day avg)#4,930

Bullish sentiment (50-day avg)100%

Price to earnings ratio6.51

Market capitalization10.7K

Earnings per share-3.07

Dividend yield (TTM)—

Revenue (annual)9.9M

Net income (annual)-164.6M

Social

What share of all stock conversation is about SYRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 20

Syros Pharmaceuticals, Inc. (SYRS) stock was recently delisted and is currently trading on the OTC market, with some investors expecting a price target of $0.16.
One investor reported selling a call option on SYRS stock and is now considering cutting losses, while others are buying and expecting a strong reversal.
The stock's price has been volatile, with some investors expecting a drop to $0.03, while others are hoping for a double in value.

Generated by AI

Sentiment

Of the messages about SYRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +19.22
Bearish	—	—	—	0% -19.22

Bullish· Mar 18

$SYRS is setting up nicely for a potential breakout, with gaps to $0.18, $0.22, and $0.24.
The company has a strong cash position, with $122.16 per share in cash, and a low float of 500K shares.
$SYRS has shown impressive momentum, up 25% since it was first identified, and is a good candidate for further gains.

Bearish· Mar 18

Syros Pharmaceuticals (SYRS) is facing delisting on March 20, 2025, after being delisted from the common stock exchange on March 10, 2025.
The stock price of SYRS is expected to continue falling, with one post citing a 15% drop in value.
Short sellers are targeting SYRS, with one post claiming a 15% drop in value at 6:22 am.

Generated by AI

Topics

Of the messages about SYRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	87.5%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	12.5%

Earnings· May 10

Syros Pharmaceuticals, Inc. ($SYRS) missed EPS loss estimates by $0.09 and also missed on revenues.
The company's earnings report was disappointing, with a significant miss on both earnings and revenue expectations.
$SYRS's earnings miss was a loss of $0.09 per share, a notable deviation from predicted losses.

Analysts· Aug 10

JMP Securities downgraded Syros Pharmaceuticals to Market Perform with a $22 price target.
Wedbush reiterated an Outperform rating with a $22.84 price target.
Cowen & Co. maintained a Buy rating on Syros Pharmaceuticals.

Announcements· Apr 9

Syros Pharmaceuticals' (SYRS) tamibarotene has received Fast Track Designation from the FDA for the treatment of newly diagnosed unfit AML with RARA gene overexpression.
The FDA's Fast Track Designation is intended to expedite the development and review of tamibarotene for this specific indication, recognizing the substantial need for a safe and effective therapy for AML patients.
Syros Pharmaceuticals announced that the FDA has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression.

Generated by AI

Community

Of the messages about SYRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	79.84%
Newcomers	—	—	0%	20.16%

Regulars· Apr 9

Syros Pharmaceuticals has received Fast Track Designation from the FDA for tamibarotene in treating newly diagnosed unfit acute myeloid leukemia (AML) with RARA gene overexpression.
The FDA's Fast Track Designation is expected to accelerate the development and potential approval of tamibarotene, which has shown promise in treating a specific subset of AML patients.
Syros Pharmaceuticals' stock price has reacted positively to the news, with the company's stock price increasing by over 8% in pre-market trading.

Newcomers· Dec 31

New users are tracking the EOD chart to see how the short sell alert played out.
The entry zone is highlighted by a yellow circle, indicating a specific area of interest.
No overnight positions were taken, suggesting a focus on day trading or short-term speculation.

Generated by AI

News

I went to a quieter Greek island instead of Mykonos and Santorini. I got beautiful beaches without fighting the crowds.

I skipped Mykonos or Santorini and visited Syros, a quieter Greek island. The beaches were stunning, the food was delicious, and it was affordable.

13d agoBusiness Insider

We moved from the US to a Greek island. Here are 5 pros and cons of raising a kid abroad.

Cara West, 35, moved her family from the US to Greece. Raising her 4-year-old abroad has been fun, but life isn't always perfect.

2mo agoBusiness Insider

Also Discussed

Investors talking about SYRS also mention

#	Name	Attention
1	Keros Therapeutics, Inc.KROS	0%new
2	Verrica Pharmaceuticals Inc.VRCA	0%0
3	CUTR - Cutera, Inc.	——
4	KRON - Kronos Bio, Inc.	——
5	Lyell Immunopharma, Inc.LYEL	0.01%new
6	Baijiayun Group LtdRTC	0%new
7	Tango Therapeutics Inc.TNGX	0%new
8	TCTM - TCTM Kids IT Education Inc.	——
9	NMHI - Nature's Miracle Holding Inc.	——
10	Sharps Technology Inc.STSS	0%0

Syros Pharmaceuticals Inc.

Healthcare
Biotechnology

Syros Pharmaceuticals Inc. is a biopharmaceutical company that focuses on discovering and developing medicines to control the expression of genes with the goal of treating diseases. The primary function of Syros Pharmaceuticals is to leverage its proprietary platform to identify and target gene regulatory regions to create therapeutics for cancer and other challenging diseases. Key features of the company include its emphasis on precision medicine, using gene regulatory analysis to pioneer drug discovery and development. Syros Pharmaceuticals plays a crucial role in the biotechnology sector by expanding treatment options for conditions that are currently underserved by existing therapies. Its innovative approach is redefining how genetic medicine can be applied to modern healthcare problems. Based in Cambridge, Massachusetts, Syros aims to produce novel therapeutics that address the underlying causes of disease, offering hope for patients through its groundbreaking scientific research and development.

Website

Location

35 CambridgePark Drive

Cambridge, MA, 02140

United States

Social

What share of all stock conversation is about SYRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 20

Syros Pharmaceuticals, Inc. (SYRS) stock was recently delisted and is currently trading on the OTC market, with some investors expecting a price target of $0.16.
One investor reported selling a call option on SYRS stock and is now considering cutting losses, while others are buying and expecting a strong reversal.
The stock's price has been volatile, with some investors expecting a drop to $0.03, while others are hoping for a double in value.

Generated by AI

Sentiment

Of the messages about SYRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +19.22
Bearish	—	—	—	0% -19.22

Bullish· Mar 18

$SYRS is setting up nicely for a potential breakout, with gaps to $0.18, $0.22, and $0.24.
The company has a strong cash position, with $122.16 per share in cash, and a low float of 500K shares.
$SYRS has shown impressive momentum, up 25% since it was first identified, and is a good candidate for further gains.

Bearish· Mar 18

Syros Pharmaceuticals (SYRS) is facing delisting on March 20, 2025, after being delisted from the common stock exchange on March 10, 2025.
The stock price of SYRS is expected to continue falling, with one post citing a 15% drop in value.
Short sellers are targeting SYRS, with one post claiming a 15% drop in value at 6:22 am.

Generated by AI

Topics

Of the messages about SYRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	87.5%
Analysts	—	—	0%	0%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	12.5%

Earnings· May 10

Syros Pharmaceuticals, Inc. ($SYRS) missed EPS loss estimates by $0.09 and also missed on revenues.
The company's earnings report was disappointing, with a significant miss on both earnings and revenue expectations.
$SYRS's earnings miss was a loss of $0.09 per share, a notable deviation from predicted losses.

Analysts· Aug 10

JMP Securities downgraded Syros Pharmaceuticals to Market Perform with a $22 price target.
Wedbush reiterated an Outperform rating with a $22.84 price target.
Cowen & Co. maintained a Buy rating on Syros Pharmaceuticals.

Announcements· Apr 9

Syros Pharmaceuticals' (SYRS) tamibarotene has received Fast Track Designation from the FDA for the treatment of newly diagnosed unfit AML with RARA gene overexpression.
The FDA's Fast Track Designation is intended to expedite the development and review of tamibarotene for this specific indication, recognizing the substantial need for a safe and effective therapy for AML patients.
Syros Pharmaceuticals announced that the FDA has granted Fast Track Designation to tamibarotene in combination with azacitidine and venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) with RARA overexpression.

Generated by AI

Community

Of the messages about SYRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	79.84%
Newcomers	—	—	0%	20.16%

Regulars· Apr 9

Syros Pharmaceuticals has received Fast Track Designation from the FDA for tamibarotene in treating newly diagnosed unfit acute myeloid leukemia (AML) with RARA gene overexpression.
The FDA's Fast Track Designation is expected to accelerate the development and potential approval of tamibarotene, which has shown promise in treating a specific subset of AML patients.
Syros Pharmaceuticals' stock price has reacted positively to the news, with the company's stock price increasing by over 8% in pre-market trading.

Newcomers· Dec 31

New users are tracking the EOD chart to see how the short sell alert played out.
The entry zone is highlighted by a yellow circle, indicating a specific area of interest.
No overnight positions were taken, suggesting a focus on day trading or short-term speculation.

Generated by AI

Syros Pharmaceuticals

Social

Mar 20

Bullish· Mar 18

Bearish· Mar 18

Earnings· May 10

Analysts· Aug 10

Announcements· Apr 9

Regulars· Apr 9

Newcomers· Dec 31

I went to a quieter Greek island instead of Mykonos and Santorini. I got beautiful beaches without fighting the crowds.

We moved from the US to a Greek island. Here are 5 pros and cons of raising a kid abroad.

Also Discussed

Syros Pharmaceuticals Inc.

Company Information

Location

I went to a quieter Greek island instead of Mykonos and Santorini. I got beautiful beaches without fighting the crowds.

We moved from the US to a Greek island. Here are 5 pros and cons of raising a kid abroad.

Also Discussed

Social

Mar 20

Bullish· Mar 18

Bearish· Mar 18

Earnings· May 10

Analysts· Aug 10

Announcements· Apr 9

Regulars· Apr 9

Newcomers· Dec 31